Biogen (BIIB) said, for 2026, it now expects adjusted EPS in a range of $14.25 to $15.25, revised from prior guidance range of $15.25 to $16.25. Biogen updated its guidance to reflect an approximately $1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy. This comprises approximately $0.20 recorded in the first quarter and approximately $0.80 expected in the second quarter. The updated guidance excludes the anticipated Apellis transaction.
Biogen said its fiscal 2026 total revenue is expected to decline by a mid-single digit percentage as compared to 2025 as further declines in multiple sclerosis product revenue, excluding VUMERITY, are expected to be partially offset by increases in revenue from growth products. The company expects MS product revenue, excluding VUMERITY, to decline by a mid-teen percentage. Biosimilars are expected to continue to decline by low double-digit percentage.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.